Journal of Clinical and Experimental Hepatology最新文献

{"title":"Issue Highlights","authors":"","doi":"10.1016/j.jceh.2026.103483","DOIUrl":"10.1016/j.jceh.2026.103483","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"16 1","pages":"Article 103483"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Genetic Protection: Revisiting Hepatic Resilience in Prader-Willi Syndrome","authors":"Nathkapach K. Rattanapitoon, Chutharat Thanchonnang, Patpicha Arunsan, Schawanya K. Rattanapitoon","doi":"10.1016/j.jceh.2025.103419","DOIUrl":"10.1016/j.jceh.2025.103419","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"16 1","pages":"Article 103419"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Brief Report on Identification of Splice Variants in an In Vitro 3D Spheroid Model for Differentiated Hepatocellular Carcinoma","authors":"Shreyas H. Karunakara,&nbsp;Rohit Mehtani,&nbsp;Gopalakrishna Ramaswamy,&nbsp;Vinutha S. Puttamallapa,&nbsp;Prashant M. Vishwanath,&nbsp;Prasanna K. Santhekadur","doi":"10.1016/j.jceh.2025.103151","DOIUrl":"10.1016/j.jceh.2025.103151","url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) represents the major form of primary liver cancer. Alternative splicing events (ASEs) are critical to generating mRNA splice variants that can dictate cell fate during HCC development. We report different ASEs in a 3D <em>in vitro</em> HCC spheroid model. This short study serves as a template to design functional studies to target different splicing events in different subtypes of hepatocellular carcinoma.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 6","pages":"Article 103151"},"PeriodicalIF":3.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cystic Duct Anastomosis as a Rescue Strategy to Deal With a Separated Segment 2 Bile Duct During Right Lobe Donor Hepatectomy With Variant Biliary Anatomy","authors":"Prasanna Gopal,&nbsp;Sathish K. Krishnan,&nbsp;Rajanikanth Patcha,&nbsp;Selvakumar Malleeswaran,&nbsp;Joy Varghese,&nbsp;Mettu S. Reddy","doi":"10.1016/j.jceh.2025.102626","DOIUrl":"10.1016/j.jceh.2025.102626","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 6","pages":"Article 102626"},"PeriodicalIF":3.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144886715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Air Leak Syndrome After Percutaneous-endoscopic Rendezvous for Malignant Biliary Obstruction: A Case Report","authors":"Jie Tan,&nbsp;Zhuo Li,&nbsp;Zhi-Jun Li,&nbsp;Peng Yan","doi":"10.1016/j.jceh.2025.103158","DOIUrl":"10.1016/j.jceh.2025.103158","url":null,"abstract":"<div><div>Endoscopic retrograde cholangiopancreatography (ERCP) is a key therapeutic tool for biliary access, but cannulation failure occurs in 5%–10% of cases. We report a 92-year-old woman with obstructive jaundice and complete distal common bile duct obstruction, in whom standard ERCP failed. A percutaneous-endoscopic rendezvous (PE-RV) approach successfully established biliary drainage via a transhepatic guidewire and stent placement. However, the patient developed pneumoperitoneum, tension pneumothorax, and subcutaneous emphysema following abrupt catheter removal. These manifestations are collectively referred to as “air leak syndrome,” which encompasses the abnormal presence of air in the peritoneal cavity, pleural space, and subcutaneous tissue. Imaging showed no pneumoretroperitoneum, suggesting gas migration through an immature percutaneous tract. Urgent drainage and antibiotics led to gradual recovery. This case highlights PE-RV as a valuable salvage technique but underscores the risk of rare gas-related complications when percutaneous tract closure is premature. To minimize the risk of such complications, procedural protocols may need to incorporate delayed catheter removal or tract embolization to ensure safe outcomes. Careful catheter management, delayed removal, and interdisciplinary coordination are essential for safe outcomes.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 6","pages":"Article 103158"},"PeriodicalIF":3.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145026360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Letter to Editor: Predictors of Mortality in Patients Diagnosed With Autoimmune Hepatitis","authors":"Harsh J. Gandhi ,&nbsp;Shubham Jain,&nbsp;Pravin Rathi","doi":"10.1016/j.jceh.2025.102609","DOIUrl":"10.1016/j.jceh.2025.102609","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 6","pages":"Article 102609"},"PeriodicalIF":3.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fatal Herpes Simplex Hepatitis in a Live Liver Donor.","authors":"Sanjay Govil, Jayanth Reddy, Sandeep Satsangi, Raje Gowda, Karthik Raichurkar, Anindita Mukherjee, Nagesh Pn, Jayasree Shivadasan, Mukul Vij","doi":"10.1016/j.jceh.2025.103116","DOIUrl":"10.1016/j.jceh.2025.103116","url":null,"abstract":"<p><p>We present a case report of a living liver donor death from Herpes simplex hepatitis, highlighting the need for vigilance regarding rare but treatable causes of acute liver failure after donor hepatectomy. Early consideration of HSV hepatitis and prompt initiation of antiviral therapy may improve outcomes.</p>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 6","pages":"103116"},"PeriodicalIF":3.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy and Safety of First-Line Treatment With Atezolizumab/Bevacizumab vs. Tyrosine-kinase Inhibitors in Patients With Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-analysis","authors":"Sakditad Saowapa ,&nbsp;Natchaya Polpichai ,&nbsp;Pojsakorn Danpanichkul ,&nbsp;Romelia B. Bernal ,&nbsp;Pharit Siladech ,&nbsp;Lukman Tijani ,&nbsp;Kenrick Ng ,&nbsp;Yu J. Wong ,&nbsp;Ashok Choudhury ,&nbsp;Surasak Saokaew ,&nbsp;Suthat Liangpunsakul ,&nbsp;Apichat Kaewdech","doi":"10.1016/j.jceh.2025.102633","DOIUrl":"10.1016/j.jceh.2025.102633","url":null,"abstract":"<div><h3>Background/Aims</h3><div>Sorafenib, lenvatinib, and atezolizumab combined with bevacizumab (Atezo/Bev) are approved first-line treatments for unresectable hepatocellular carcinoma (uHCC). However, direct comparisons among these therapies remain limited. This study aims to compare the efficacy and safety of Atezo/Bev versus tyrosine-kinase inhibitors (TKIs) as first-line therapies for uHCC.</div></div><div><h3>Methods</h3><div>Two independent authors conducted a literature search using electronic databases (Google Scholar, Medline, and PubMed) and manual reference list reviews up to June 2024. We included studies reporting on overall survival (OS), progression free survival (PFS) or safety data comparing Atezo/Bev versus TKI (sorafenib or lenvatinib) in patients with uHCC, irrespective of study design. Data extraction and statistical analysis were performed using RevMan 5.4.</div></div><div><h3>Results</h3><div>We included a total of 12 studies (Ten retrospective cohort studies, one prospective study, one randomized controlled trial) involving 9952 patients (3560 received Atezo/Bev combination therapy and 6392 received TKI). Atezo/Bev significantly improved OS and PFS compared to lenvatinib (HR: 0.79, 95% CI: 0.71–0.89, <em>P</em> = 0.0001 for OS; HR: 0.76, 95% CI: 0.64–0.90, <em>P</em> = 0.002 for PFS). Atezo/Bev also improved OS in viral patients (HR: 0.72, 95% CI: 0.60–0.86, <em>P</em> = 0.0004), while lenvatinib improved OS (HR: 1.36, 95% CI: 1.13–1.65, <em>P</em> = 0.001) and PFS (HR: 1.46, 95% CI: 1.04–2.05, <em>P</em> = 0.03) in nonviral patients. Atezo/Bev had fewer grade ≥3 adverse events than lenvatinib (OR: 0.43, 95% CI: 0.36–0.51, <em>P</em> = 0.03). Atezo/Bev also demonstrated superior OS and PFS compared to sorafenib (HR: 0.68, 95% CI: 0.57–0.81, <em>P</em> &lt; 0.00001 for OS; HR: 0.67, 95% CI: 0.57–0.77, <em>P</em> &lt; 0.00001 for PFS).</div></div><div><h3>Conclusions</h3><div>Atezo/Bev demonstrates better survival outcomes and safety profile compared to TKI. However, for patients with HCC of nonviral etiology, lenvatinib may be a more suitable alternative.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 6","pages":"Article 102633"},"PeriodicalIF":3.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144695212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Interaction of Human Factors and Resistance-associated Substitutions in Hepatitis C Elimination","authors":"Judah Kupferman,&nbsp;Paul Y. Kwo","doi":"10.1016/j.jceh.2025.103188","DOIUrl":"10.1016/j.jceh.2025.103188","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 6","pages":"Article 103188"},"PeriodicalIF":3.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145264937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward Real-time Detection of Drug-induced Liver Injury Using Large Language Models: A Feasibility Study From Clinical Notes","authors":"Thanathip Suenghataiphorn ,&nbsp;Pojsakorn Danpanichkul ,&nbsp;Narisara Tribuddharat ,&nbsp;Narathorn Kulthamrongsri","doi":"10.1016/j.jceh.2025.102627","DOIUrl":"10.1016/j.jceh.2025.102627","url":null,"abstract":"<div><h3>Background</h3><div>Drug-induced liver injury (DILI) is a significant clinical problem. Current detection methods are often delayed. Real-time analysis of electronic medical records (EMRs) using a large language model (LLM) could enable earlier surveillance.</div></div><div><h3>Objective</h3><div>To evaluate the technical feasibility of an LLM-powered system for real-time DILI identification assessment by extracting medication information from unstructured clinical notes.</div></div><div><h3>Methods</h3><div>We developed a system using a large language model (LLM) to extract medication lists from clinical text. Prompts were iteratively refined for optimal performance. We integrated DILI risk data from DILIrank and LiverTox, utilizing LLM and algorithmic matching to link extracted medications to database entries. We utilized the RxNORM database and manual mistyped medication, as well as the NHANES database for a structured medication list, to verify accurate results.</div></div><div><h3>Results</h3><div>Using 30 entries each from NHANES, RxNORM, and real-world cases, the LLM-based medication extraction achieved a precision of 0.96, recall of 0.97, and an F1-score of 0.97%. For NHANES data, no errors were found. Applying to real-world cases and mistyped dataset, the LLM-based extraction fared acceptably, with F1-scores of 0.94 and 0.97, respectively. The majority of error are due to trade name and combined medication names.</div></div><div><h3>Conclusion</h3><div>This study demonstrates the potential of LLMs for accurate medication extraction from clinical notes, a crucial step towards real-time DILI risk assessment. However, the system requires further development and clinical validation before implementation. Future work will focus on matching methods, clinical validation, EMR integration, and development of an agentic AI to triage future DILI risk.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 6","pages":"Article 102627"},"PeriodicalIF":3.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144587793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}